Download PDF
Semin Respir Crit Care Med 2009; 30(4): 484-492
DOI: 10.1055/s-0029-1233317
© Thieme Medical Publishers

Medical Treatment of Pulmonary Arterial Hypertension

Huzaifa Adamali1 , Sean P. Gaine1 , Lewis J. Rubin2
  • 1Department of Respiratory Medicine, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland
  • 2Division of Pulmonary and Critical Care Medicine, University of California at San Diego, San Diego, California
Further Information

Publication History

Publication Date:
24 July 2009 (online)

    Permissions and Reprints

ABSTRACT

Pulmonary arterial hypertension (PAH) is a sinister condition that is often diagnosed late and is associated with a progressive clinical deterioration and premature death. However, over the past 10 years the field has seen a dramatic increase in the number of effective therapies underpinned by advances in our understanding of the pathobiology of this illness. Identification of dysfunctional signaling pathways in the pulmonary circulation provided novel therapeutic targets with the goal of reducing pulmonary vascular resistance and prevention of death from right ventricular failure. Treatment algorithms have now become more complex, with therapeutic options defined by pulmonary artery vasoreactivity, functional class, and response to treatment. Combination therapies are increasingly considered as clinical trials demonstrating the efficacy of this approach are emerging. Monitoring and measuring the response to treatment in clinical trials and clinical practice are evolving from the historical dependence on functional class and 6-minute walk test to include estimates of the delay in the time to clinical worsening and the response of emerging biomarkers.

KEYWORDS

Pulmonary arterial hypertension - medical treatment - combination therapy

REFERENCES

  • 1 Badesch D B, Abman S H, Simonneau G, Rubin L J, McLaughlin V V. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.  Chest. 2007;  131 1917-1928
    CrossrefPubMedGoogle Scholar
  • 2 Galiè N, Torbicki A, Barst R et al.. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.  Eur Heart J. 2004;  25 2243-2278
    CrossrefPubMedGoogle Scholar
  • 3 Simonneau G, Galiè N, Rubin L J et al.. Clinical classification of pulmonary hypertension.  J Am Coll Cardiol. 2004;  43(12, Suppl S) 5S-12S
    CrossrefPubMedGoogle Scholar
  • 4 Mereles D, Ehlken N, Kreuscher S et al.. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension.  Circulation. 2006;  114 1482-1489
    CrossrefPubMedGoogle Scholar
  • 5 Weiss B M, Zemp L, Seifert B, Hess O M. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996.  J Am Coll Cardiol. 1998;  31 1650-1657
    CrossrefPubMedGoogle Scholar
  • 6 Parambil J G, McGoon M D. Pregnancy and pulmonary hypertension. In: Oakley C, Warnes CA Heart Disease in Pregnancy. Malden, MA; Blackwell 2007: 59-78
    Google Scholar
  • 7 Chan W S, Anand S, Ginsberg J S. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature.  Arch Intern Med. 2000;  160 191-196
    CrossrefPubMedGoogle Scholar
  • 8 Kenyon K W, Nappi J M. Bosentan for the treatment of pulmonary arterial hypertension.  Ann Pharmacother. 2003;  37 1055-1062
    CrossrefPubMedGoogle Scholar
  • 9 Warnes C A. Pregnancy and pulmonary hypertension.  Int J Cardiol. 2004;  97(Suppl 1) 11-13
    CrossrefPubMedGoogle Scholar
  • 10 Tarver J H, Rosas I, Diette G B et al.. Chronic ambulatory dopamine infusion therapy for refractory right heart failure due to pulmonary hypertension [abstract].  ARRCM. 2000;  161 A459
    PubMedGoogle Scholar
  • 11 Fuster V, Steele P M, Edwards W D, Gersh B J, McGoon M D, Frye R L. Primary pulmonary hypertension: natural history and the importance of thrombosis.  Circulation. 1984;  70 580-587
    CrossrefPubMedGoogle Scholar
  • 12 Johnson S R, Granton J T, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension.  Chest. 2006;  130 545-552
    CrossrefPubMedGoogle Scholar
  • 13 Kawut S M, Horn E M, Berekashvili K K et al.. New predictors of outcome in idiopathic pulmonary arterial hypertension.  Am J Cardiol. 2005;  95 199-203
    CrossrefPubMedGoogle Scholar
  • 14 Rich S, Seidlitz M, Dodin E et al.. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension.  Chest. 1998;  114 787-792
    CrossrefPubMedGoogle Scholar
  • 15 Rich S, Brundage B H. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.  Circulation. 1987;  76 135-141
    CrossrefPubMedGoogle Scholar
  • 16 Rubin L J, Badesch D B, Barst R J et al.. Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 2002;  346 896-903
    CrossrefPubMedGoogle Scholar
  • 17 Sitbon O, Humbert M, Jaïs X et al.. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.  Circulation. 2005;  111 3105-3111
    CrossrefPubMedGoogle Scholar
  • 18 Barst R J, Rubin L J, Long W A The Primary Pulmonary Hypertension Study Group et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.  N Engl J Med. 1996;  334 296-302
    CrossrefPubMedGoogle Scholar
  • 19 Badesch D B, Tapson V F, McGoon M D et al.. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial.  Ann Intern Med. 2000;  132 425-434
    PubMedGoogle Scholar
  • 20 Jones D A, Benjamin C W, Linseman D A. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades.  Mol Pharmacol. 1995;  48 890-896
    PubMedGoogle Scholar
  • 21 Rubin L J, Mendoza J, Hood M et al.. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial.  Ann Intern Med. 1990;  112 485-491
    CrossrefPubMedGoogle Scholar
  • 22 McLaughlin V V, Genthner D E, Panella M M, Hess D M, Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series.  Ann Intern Med. 1999;  130 740-743
    PubMedGoogle Scholar
  • 23 Rosenzweig E B, Kerstein D, Barst R J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.  Circulation. 1999;  99 1858-1865
    CrossrefPubMedGoogle Scholar
  • 24 Krowka M J, Frantz R P, McGoon M D, Severson C, Plevak D J, Wiesner R H. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension.  Hepatology. 1999;  30 641-648
    CrossrefPubMedGoogle Scholar
  • 25 Nunes H, Humbert M, Sitbon O et al.. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2003;  15 1433-1439
    PubMedGoogle Scholar
  • 26 Cabrol S, Souza R, Jais X et al.. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.  J Heart Lung Transplant. 2007;  26 357-362
    CrossrefPubMedGoogle Scholar
  • 27 Rich S, McLaughlin V V. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension.  J Am Coll Cardiol. 1999;  34 1184-1187
    CrossrefPubMedGoogle Scholar
  • 28 McLaughlin V V, Gaine S P, Barst R J Treprostinil Study Group et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension.  J Cardiovasc Pharmacol. 2003;  41 293-299
    CrossrefPubMedGoogle Scholar
  • 29 Vachiéry J L, Hill N, Zwicke D, Barst R, Blackburn S, Naeije R. Transitioning from I.V. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension.  Chest. 2002;  121 1561-1565
    CrossrefPubMedGoogle Scholar
  • 30 Tapson V F, McLaughlin V V, Gomberg-Maitland M et al.. Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension.  J Vasc Access. 2006;  7 112-117
    PubMedGoogle Scholar
  • 31 Simonneau G, Barst R J, Galie N Treprostinil Study Group et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.  Am J Respir Crit Care Med. 2002;  165 800-804
    CrossrefPubMedGoogle Scholar
  • 32 Barst R J, Galie N, Naeije R et al.. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.  Eur Respir J. 2006;  28 1195-1203
    CrossrefPubMedGoogle Scholar
  • 33 Olschewski H, Simonneau G, Galiè N Aerosolized Iloprost Randomized Study Group et al. Inhaled iloprost for severe pulmonary hypertension.  N Engl J Med. 2002;  347 322-329
    CrossrefPubMedGoogle Scholar
  • 34 Opitz C F, Wensel R, Winkler J et al.. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension.  Eur Heart J. 2005;  26 1895-1902
    CrossrefPubMedGoogle Scholar
  • 35 Higenbottam T, Butt A Y, McMahon A, Westerbeck R, Sharples L. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension.  Heart. 1998;  80 151-155
    PubMedGoogle Scholar
  • 36 Galiè N, Humbert M, Vachiéry J L Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.  J Am Coll Cardiol. 2002;  39 1496-1502
    CrossrefPubMedGoogle Scholar
  • 37 Barst R J, McGoon M, McLaughlin V Beraprost Study Group et al. Beraprost therapy for pulmonary arterial hypertension.  J Am Coll Cardiol. 2003;  41 2119-2125
    CrossrefPubMedGoogle Scholar
  • 38 Giaid A, Yanagisawa M, Langleben D et al.. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.  N Engl J Med. 1993;  328 1732-1739
    CrossrefPubMedGoogle Scholar
  • 39 Rubin L J, Badesch D B, Barst R J et al.. Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 2002;  346 896-903
    CrossrefPubMedGoogle Scholar
  • 40 Dupuis J. Endothelin-receptor antagonists in pulmonary hypertension.  Lancet. 2001;  358 1113-1114
    CrossrefPubMedGoogle Scholar
  • 41 Dupuis J, Jasmin J F, Prié S, Cernacek P. Importance of local production of endothelin-1 and of the ET(B) receptor in the regulation of pulmonary vascular tone.  Pulm Pharmacol Ther. 2000;  13 135-140
    CrossrefPubMedGoogle Scholar
  • 42 Kirchengast M, Luz M. Endothelin receptor antagonists: clinical realities and future directions.  J Cardiovasc Pharmacol. 2005;  45 182-191
    CrossrefPubMedGoogle Scholar
  • 43 Channick R N, Simonneau G, Sitbon O et al.. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.  Lancet. 2001;  358 1119-1123
    CrossrefPubMedGoogle Scholar
  • 44 McLaughlin V V, Sitbon O, Badesch D B et al.. Survival with first-line bosentan in patients with primary pulmonary hypertension.  Eur Respir J. 2005;  25 244-249
    CrossrefPubMedGoogle Scholar
  • 45 Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.  Eur Heart J. 2006;  27 589-595
    CrossrefPubMedGoogle Scholar
  • 46 Galié N, Badesch D, Oudiz R et al.. Ambrisentan therapy for pulmonary arterial hypertension.  J Am Coll Cardiol. 2005;  46 529-535
    CrossrefPubMedGoogle Scholar
  • 47 Galiè N, Olschewski H, Oudiz R J Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.  Circulation. 2008;  117 3010-3019
    CrossrefPubMedGoogle Scholar
  • 48 Oudiz R, Badesch D, Rubin L. ARIES-E: Long-term safety and efficacy of ambrisentan in pulmonary arterial hypertension [abstract].  Chest. 2007;  132 474a
    PubMedGoogle Scholar
  • 49 Barst R J, Langleben D, Badesch D STRIDE-2 Study Group et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.  J Am Coll Cardiol. 2006;  47 2049-2056
    CrossrefPubMedGoogle Scholar
  • 50 Barst R J. Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension.  Expert Opin Pharmacother. 2007;  8 95-109
    CrossrefPubMedGoogle Scholar
  • 51 Barst R J, Langleben D, Frost A STRIDE-1 Study Group et al. Sitaxsentan therapy for pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2004;  169 441-447
    CrossrefPubMedGoogle Scholar
  • 52 Barst R J, Langleben D, Badesch D STRIDE-2 Study Group et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.  J Am Coll Cardiol. 2006;  47 2049-2056
    CrossrefPubMedGoogle Scholar
  • 53 Benza R L, Mehta S, Keogh A, Lawrence E C, Oudiz R J, Barst R J. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.  J Heart Lung Transplant. 2007;  26 63-69
    CrossrefPubMedGoogle Scholar
  • 54 Langleben D, Hirsch A M, Shalit E, Lesenko L, Barst R J. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study.  Chest. 2004;  126 1377-1381
    CrossrefPubMedGoogle Scholar
  • 55 Galiè N, Ghofrani H A, Torbicki A Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group et al. Sildenafil citrate therapy for pulmonary arterial hypertension.  N Engl J Med. 2005;  353 2148-2157
    CrossrefPubMedGoogle Scholar
  • 56 Pepke-Zaba J, Gilbert C, Collings L, Brown M C. Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension.  Chest. 2008;  133 183-189
    CrossrefPubMedGoogle Scholar
  • 57 Galiè N et al.. Tadalafil therapy for pulmonary arterial hypertension.  Circulation. 2009;  119 2894-2903
    CrossrefPubMedGoogle Scholar
  • 58 Simonneau G, Rubin L J, Galiè N PACES Study Group et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.  Ann Intern Med. 2008;  149 521-530
    CrossrefPubMedGoogle Scholar
  • 59 Wilkens H, Guth A, König J et al.. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension.  Circulation. 2001;  104 1218-1222
    CrossrefPubMedGoogle Scholar
  • 60 Ghofrani H A, Rose F, Schermuly R T et al.. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.  J Am Coll Cardiol. 2003;  42 158-164
    CrossrefPubMedGoogle Scholar
  • 61 Ghofrani H A, Wiedemann R, Rose F et al.. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.  Ann Intern Med. 2002;  136 515-522
    CrossrefPubMedGoogle Scholar
  • 62 United Therapeutics .TRIUMPH-1 trial of Viveta in pulmonary arterial hypertension meets primary endpoint. November 1, 2007. Available at: http://ir.unither.com/releasedetail.cfm?ReleaseID=272478
    Google Scholar
  • 63 McLaughlin V V, Oudiz R J, Frost A et al.. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2006;  174 1257-1263
    CrossrefPubMedGoogle Scholar
  • 64 Hoeper M M, Leuchte H, Halank M et al.. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension.  Eur Respir J. 2006;  28 691-694
    CrossrefPubMedGoogle Scholar
  • 65 Humbert M, Barst R J, Robbins I M et al.. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.  Eur Respir J. 2004;  24 353-359
    CrossrefPubMedGoogle Scholar
  • 66 Hoeper M M, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.  Eur Respir J. 2004;  24 1007-1010
    CrossrefPubMedGoogle Scholar
  • 67 Mathai S C, Girgis R E, Fisher M R et al.. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.  Eur Respir J. 2007;  29 469-475
    CrossrefPubMedGoogle Scholar
  • 68 Doyle R L, McCrory D, Channick R N, Simonneau G, Conte J. American College of Chest Physicians . Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.  Chest. 2004;  126(1, Suppl) 63S-71S
    CrossrefPubMedGoogle Scholar
  • 69 Orens J B, Estenne M, Arcasoy S et al.. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation.  J Heart Lung Transplant. 2006;  25 745-755
    CrossrefPubMedGoogle Scholar
  • 70 American Academy of Hospice and Palliative Medicine . National Consensus Project for Quality Palliative Care: Clinical Practice Guidelines for quality palliative care, executive summary.  J Palliat Med. 2004;  7 611-627
    CrossrefPubMedGoogle Scholar
  • 71 Hoeper M M, Galié N, Murali S et al.. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2002;  165 341-344
    CrossrefPubMedGoogle Scholar
  • 72 McKenna S P, Doughty N, Meads D M, Doward L C, Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension.  Qual Life Res. 2006;  15 103-115
    CrossrefPubMedGoogle Scholar
  • 73 Nagaya N, Nishikimi T, Goto Y et al.. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction.  Am Heart J. 1998;  135 21-28
    CrossrefPubMedGoogle Scholar
  • 74 Leuchte H H, Holzapfel M, Baumgartner R A et al.. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension.  J Am Coll Cardiol. 2004;  43 764-770
    CrossrefPubMedGoogle Scholar
  • 75 Nagaya N, Nishikimi T, Uematsu M et al.. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension.  Circulation. 2000;  102 865-870
    CrossrefPubMedGoogle Scholar
  • 76 Fijalkowska A, Kurzyna M, Torbicki A et al.. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.  Chest. 2006;  129 1313-1321
    CrossrefPubMedGoogle Scholar
  • 77 Raymond R J, Hinderliter A L, Willis P W et al.. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension.  J Am Coll Cardiol. 2002;  39 1214-1219
    CrossrefPubMedGoogle Scholar
  • 78 Yeo T C, Dujardin K S, Tei C, Mahoney D W, McGoon M D, Seward J B. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension.  Am J Cardiol. 1998;  81 1157-1161
    CrossrefPubMedGoogle Scholar
  • 79 Forfia P R, Fisher M R, Mathai S C et al.. Tricuspid annular displacement predicts survival in pulmonary hypertension.  Am J Respir Crit Care Med. 2006;  174 1034-1041
    CrossrefPubMedGoogle Scholar
  • 80 Frantz R P, Benza R L, Kjellström B et al.. Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension.  J Heart Lung Transplant. 2008;  27 780-788
    CrossrefPubMedGoogle Scholar

Sean P GaineM.D. Ph.D. 

Department of Respiratory Medicine, Mater Misericordiae University Hospital

University College Dublin, Eccles St., Dublin 7, Ireland

Email: sgaine@o2.ie

      >